MHRA publishes a new guidance in case of a hard Brexit
The British Medicines and Healthcare products Regulatory Agency (MHRA) has published a new guidance on the regulation of medicines, medical devices and clinical trials in case of a hard Brexit. The guidance is a useful tool in the preparations for a hard Brexit, the risk of which has just increased after the British Parliament on January 15 rejected the Brexit deal.
Read the guidance note:
"Further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal"
Read more about the consequences of a hard Brexit in this Insight, where Plesner's Brexit Task Force provides an overall view of a number of important legal areas:
"Overview: Consequences of a hard Brexit"